The CD19 Inebilizu Biosimilar (HDBS0050) is a targeted therapy designed to inhibit immune responses by targeting the CD19 protein on B cells. This biosimilar antibody, similar to inebilizumab, binds specifically to CD19, leading to the depletion of B cells and reducing inflammation. Developed as a potential treatment for autoimmune disorders, B cell malignancies, and other immune-related diseases, the CD19 Inebilizu Biosimilar shows promise in modulating the immune response and controlling disease progression. With its ability to target and neutralize CD19-expressing cells, this biosimilar offers a targeted approach to managing immune dysregulation.
The Anti-CD19 Inebilizu Biosimilar (HDBS0050) provides a novel therapeutic option for researchers and clinicians studying immune system modulation and seeking new avenues for treating autoimmune disorders and B cell malignancies. Its specificity for CD19 makes it a valuable tool for investigating the role of B cells in disease pathogenesis and developing targeted therapies for immune-related conditions.
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
MEDI-551,Medi-551
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
ELISA, Flow Cyt
Antibody Isotype:
IgG1
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
